Sherry Pierce

25.4k citations
430 papers · 14.9k · 1 hit paper · h-index 61

Impact in

  • Hematology top 0.02%
    • Acute Myeloid Leukemia Research
    • Chronic Myeloid Leukemia Treatments
    • Hematopoietic Stem Cell Transplantation
  • Genetics top 0.05%
    • Myeloproliferative Neoplasms: Diagnosis and Treatment
    • Chronic Lymphocytic Leukemia Research

Papers in

  • Hematology 338
    • Acute Myeloid Leukemia Research 287
    • Chronic Myeloid Leukemia Treatments 95
    • Multiple Myeloma Research and Treatments 28
  • Genetics 163
    • Myeloproliferative Neoplasms: Diagnosis and Treatment 105
    • Chronic Lymphocytic Leukemia Research 54
Co-authors
Hagop M. Kantarjian (251 shared papers)Jörge E. Cortes (230 shared papers)Elihu H. Estey (65 shared papers)Guillermo Garcia‐Manero (243 shared papers)Farhad Ravandi (217 shared papers)Michael J. Keating (50 shared papers)Susan O’Brien (88 shared papers)Stefan Faderl (82 shared papers)
Journals
Blood (174 papers)Cancer (44 papers)Journal of Clinical Oncology (40 papers)American Journal of Hematology (24 papers)Leukemia Research (16 papers)
Partner nations
United StatesJapanSpain

In The Last Decade

Sherry Pierce

418 papers receiving 14.7k citations

Sherry Pierce's Hit Papers

Results of Treatment With Hyper-CVAD, a Dose-Intensive Regimen, in Adult Acute Lymphocytic Leukemia 2000 · 592 citations
5920+8+17Years since publication100200300400500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

  • it has ≥500 total citations;
  • it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
  • it reaches the top citation threshold in at least one of its specific research topics.
  1. 2000 Journal of Clinical Oncology

Peers

Sherry Pierce
Comparison fields: 5 of 132
  • Hematology 9.7k
  • Genetics 4.0k
  • Public Health, Environmental and Occupational Health 3.6k
  • Oncology 2.5k
  • Pathology and Forensic Medicine 1.4k
Replace Hervé Dombret with:
Hervé Dombret France
Alan F. List United States
Mikkael A. Sekeres United States
Norbert Ifrah France
Charles Koller United States
Nigel H. Russell United Kingdom
Meir Wetzler United States
Uwe Platzbecker Germany
Norbert Vey France
Peter L. Greenberg United States
Sherry Pierce relative to Hervé Dombret France Hervé Dombret's profile →
Citations per field
00.5×1.5×
Hervé Dombret · 1×
Citations per year

Countries citing papers authored by Sherry Pierce

Since Specialization
Citations

This map shows the geographic impact of Sherry Pierce's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sherry Pierce with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sherry Pierce more than expected).

Fields of papers citing papers by Sherry Pierce

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sherry Pierce. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sherry Pierce. The network helps show where Sherry Pierce may publish in the future.

Co-authors

The 25 scholars most cited alongside Sherry Pierce, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Sherry Pierce Line = papers co-authored together Sherry Pierce links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 430 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Results of Treatment With Hyper-CVAD, a Dose-Intensive Regimen, in Adult Acute Lymphocytic Leukemia
Journal of Clinical Oncology ·Hagop M. Kantarjian, Susan O’Brien, Terry L. Smith, Jörge E. Cortes, Francis J. Giles, Miloslav Beran, Sherry Pierce, Yang O. Huh, Michael Andreeff, Charles Koller, Chul S. Ha, Michael J. Keating, Sharon Murphy, Emil J. Freireich
Hit paper breakdown →		2000592
2
Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high‐risk myelodysplastic syndrome:
Cancer ·Hagop M. Kantarjian, Susan O’Brien, Jörge E. Cortes, Francis J. Giles, Stefan Faderl, Elias Jabbour, Guillermo Garcia‐Manero, William G. Wierda, Sherry Pierce, Jianqin Shan, Elihu H. Estey
2006470
3
Long‐term follow‐up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper‐CVAD), a dose‐intensive regimen, in adult acute lymphocytic leukemia
Cancer ·Hagop M. Kantarjian, Deborah A. Thomas, Susan O’Brien, Jörge E. Cortes, Francis J. Giles, Sima Jeha, Carlos E. Bueso‐Ramos, Sherry Pierce, Jianqin Shan, Charles Koller, Miloslav Beran, Michael J. Keating, Emil J. Freireich
2004461
4
Chemoimmunotherapy with hyper‐CVAD plus rituximab for the treatment of adult Burkitt and Burkitt‐type lymphoma or acute lymphoblastic leukemia
Cancer ·Deborah A. Thomas, Stefan Faderl, Susan O’Brien, Carlos E. Bueso‐Ramos, Jörge E. Cortes, Guillermo Garcia‐Manero, Francis J. Giles, Srđan Verstovšek, William G. Wierda, Sherry Pierce, Jianqin Shan, Mark Brandt, Fredrick B. Hagemeister, Michael J. Keating, Fernando Cabanillas, Hagop M. Kantarjian
2006371
5
Chemoimmunotherapy With a Modified Hyper-CVAD and Rituximab Regimen Improves Outcome in De Novo Philadelphia Chromosome–Negative Precursor B-Lineage Acute Lymphoblastic Leukemia
Journal of Clinical Oncology ·Deborah A. Thomas, Susan O’Brien, Stefan Faderl, Guillermo Garcia‐Manero, Alessandra Ferrajoli, William G. Wierda, Farhad Ravandi, Srđan Verstovšek, Jeffrey L. Jorgensen, Carlos E. Bueso‐Ramos, Michael Andreeff, Sherry Pierce, Rebecca Garris, Michael J. Keating, Jörge E. Cortes, Hagop M. Kantarjian
2010307
6
Pegylated Interferon Alfa-2a Yields High Rates of Hematologic and Molecular Response in Patients With Advanced Essential Thrombocythemia and Polycythemia Vera
Journal of Clinical Oncology ·Alfonso Quintás‐Cardama, Hagop M. Kantarjian, Taghi Manshouri, Rajyalakshmi Luthra, Zeev Estrov, Sherry Pierce, Mary Ann Richie, Gautam Borthakur, Marina Konopleva, Jörge E. Cortes, Srđan Verstovšek
2009302
7
Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome
Blood ·Andres O. Soriano, Hui Yang, Stefan Faderl, Zeev Estrov, Francis J. Giles, Farhad Ravandi, Jörge E. Cortes, William G. Wierda, Souzanne Ouzounian, Andrés Quezada, Sherry Pierce, Elihu H. Estey, Jean‐Pierre J. Issa, Hagop M. Kantarjian, Guillermo Garcia‐Manero
2007298
8
Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia
Blood ·Hagop Kantarjian, Farhad Ravandi, Susan O’Brien, Jörge E. Cortes, Stefan Faderl, Guillermo Garcia‐Manero, Elias Jabbour, William G. Wierda, Tapan M. Kadia, Sherry Pierce, Jianqin Shan, Michael A. Keating, Emil J. Freireich
2010294
9
Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation
Blood ·Farhad Ravandi, Mona Lisa Alattar, Michael R. Grunwald, Michelle A. Rudek, Trivikram Rajkhowa, Mary Ann Richie, Sherry Pierce, Naval Daver, Guillermo Garcia‐Manero, Stefan Faderl, Aziz Nazha, Marina Konopleva, Gautam Borthakur, Jan A. Burger, Tapan M. Kadia, Sara Dellasala, Michael Andreeff, Jörge E. Cortes, Hagop M. Kantarjian, Mark J. Levis
2013290
10
DNA Methylation Predicts Survival and Response to Therapy in Patients With Myelodysplastic Syndromes
Journal of Clinical Oncology ·Lanlan Shen, Hagop M. Kantarjian, Yi Guo, E. Lin, Jianqin Shan, Xuelin Huang, Donald Berry, Saira Ahmed, Wei Zhu, Sherry Pierce, Yutaka Kondo, Yasuhiro Oki, Jaroslav Jelı́nek, Hussain I. Saba, E Estey, Jean‐Pierre J. Issa
2009263
11
Prediction of Early Death After Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia With Pretreatment Risk Scores: A Novel Paradigm for Treatment Assignment
Journal of Clinical Oncology ·Roland B. Walter, Megan Othus, Gautam Borthakur, Farhad Ravandi, Jörge E. Cortes, Sherry Pierce, Frederick R. Appelbaum, Hagop Kantarjian, Elihu H. Estey
2011247
12
Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype
Blood ·Nitin Jain, Audrey L. Lamb, Susan O’Brien, Farhad Ravandi, Marina Konopleva, Elias Jabbour, Zhuang Zuo, Jeffrey L. Jorgensen, Pei Lin, Sherry Pierce, Deborah Thomas, Michael Rytting, Gautam Borthakur, Tapan M. Kadia, Jörge E. Cortes, Hagop M. Kantarjian, Joseph D. Khoury
2016223
13
Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials
The Lancet Haematology ·Koji Sasaki, Sara S. Strom, Susan O’Brien, Elias Jabbour, Farhad Ravandi, Marina Konopleva, Gautam Borthakur, Naveen Pemmaraju, Naval Daver, Preetesh Jain, Sherry Pierce, Hagop M. Kantarjian, Jörge E. Cortes
2015222
14
Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML
American Journal of Hematology ·Courtney D. DiNardo, Farhad Ravandi, Sam Agresta, Marina Konopleva, Koichi Takahashi, Tapan M. Kadia, Mark J. Routbort, Keyur P. Patel, Mark Brandt, Sherry Pierce, Guillermo Garcia‐Manero, Jörge E. Cortes, Hagop M. Kantarjian
2015216
15
The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia.
British Journal of Haematology ·Francis J. Giles, Gautam Borthakur, Farhad Ravandi, Stefan Faderl, Srđan Verstovšek, Deborah A. Thomas, William G. Wierda, Alessandra Ferrajoli, Steven M. Kornblau, Sherry Pierce, Maher Albitar, Jörge E. Cortes, Hagop M. Kantarjian
2007195
16
The incidence and impact of thrombocytopenia in myelodysplastic syndromes
Cancer ·Hagop M. Kantarjian, Francis J. Giles, Alan F. List, Roger M. Lyons, Mikkael A. Sekeres, Sherry Pierce, Robert Deuson, Joseph A. Leveque
2007180
17
Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS)
Blood ·Elihu H. Estey, Marcos de Lima, Raoul Tibes, Sherry Pierce, Hagop Kantarjian, Richard E. Champlin, Sergio Giralt
2006180
18
Effect of Diagnosis (Refractory Anemia With Excess Blasts, Refractory Anemia With Excess Blasts in Transformation, or Acute Myeloid Leukemia [AML]) on Outcome of AML-Type Chemotherapy
Blood ·Elihu H. Estey, Peter F. Thall, Miloslav Beran, Hagop M. Kantarjian, Sherry Pierce, Michael J. Keating
1997179
19
Hyper-CVAD Program in Burkitt's-Type Adult Acute Lymphoblastic Leukemia
Journal of Clinical Oncology ·Deborah A. Thomas, Jörge E. Cortes, Susan O’Brien, Sherry Pierce, Stefan Faderl, Maher Albitar, Frederick Hagemeister, Fernando Cabanillas, Sharon Murphy, Michael J. Keating, Hagop M. Kantarjian
1999178
20
Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma
Blood ·Deborah A. Thomas, Susan O’Brien, Jörge E. Cortes, Francis J. Giles, Stefan Faderl, Srđan Verstovšek, Alessandra Ferrajoli, Charles Koller, Miloslav Beran, Sherry Pierce, Chul S. Ha, Fernando Cabanillas, Michael J. Keating, Hagop M. Kantarjian
2004169

About Sherry Pierce

Sherry Pierce is a scholar working on Hematology, Genetics, Molecular Biology, Public Health, Environmental and Occupational Health and Oncology, having authored 430 papers that have together received 14.9k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (287 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (105 papers), Chronic Myeloid Leukemia Treatments (95 papers), Acute Lymphoblastic Leukemia research (57 papers), Chronic Lymphocytic Leukemia Research (54 papers), Histone Deacetylase Inhibitors Research (29 papers), Multiple Myeloma Research and Treatments (28 papers) and Retinoids in leukemia and cellular processes (27 papers). The work is most often cited by research in Hematology (9.7k citations), Genetics (4.0k citations), Public Health, Environmental and Occupational Health (3.6k citations), Oncology (2.5k citations) and Pathology and Forensic Medicine (1.4k citations). Sherry Pierce has collaborated with scholars based in United States, Japan and Spain. Frequent co-authors include Hagop M. Kantarjian, Jörge E. Cortes, Elihu H. Estey, Guillermo Garcia‐Manero, Farhad Ravandi, Michael J. Keating, Susan O’Brien, Stefan Faderl, Gautam Borthakur and Elias Jabbour. Their work appears in journals such as Blood, Cancer, Journal of Clinical Oncology, American Journal of Hematology and Leukemia Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hervé DombretBreakdown of academic impact, for papers by Alan F. ListBreakdown of academic impact, for papers by Mikkael A. SekeresBreakdown of academic impact, for papers by Norbert IfrahBreakdown of academic impact, for papers by Charles KollerBreakdown of academic impact, for papers by Nigel H. RussellBreakdown of academic impact, for papers by Meir WetzlerBreakdown of academic impact, for papers by Uwe PlatzbeckerBreakdown of academic impact, for papers by Norbert VeyBreakdown of academic impact, for papers by Peter L. Greenberg